The “World Cancer Genome Sequencing Market – Opportunities and Forecasts, 2014 – 2022” report has been added to Research and Markets’ offering.
Cancer genome sequencing refers to a method used to identify the complete DNA or RNA sequence of cancer cells based on the sequencing of a single, homogeneous or heterogeneous group of tumor cells.
It is a laboratory technique that characterizes DNA or RNA sequences of primary tumor tissue, the tumor micro environment (such as stromal / fibroblast cells), adjacent or distal normal tissue, or metastatic tumor sites.
This technique generates information related to identification of nucleotide bases (DNA or RNA), mutation status, copy number and sequence variants, as well as structural variations including fusion genes and chromosomal translocations. This technique has proved to be a breakthrough in the fight against cancer as it assists in individualization of treatment.
Development of new methods and exponential decrease in genome sequencing cost are fueling the market growth. Global cancer genome sequencing market is expected grow with a healthy CAGR due to technological advances and entry of new market players.
Agilent Technologies, GE Healthcare Life Sciences, Johnson & Johnson, LI-COR Biosciences (Lincoln, NE), Abbott Laboratories, Beckman Coulter (Fullerton, CA), Bayer Corporation, Hamilton Thorne Biosciences, Integrated DNA Technologies, Microchip Biotechnologies, Myriad Genetics, Commonwealth Biotechnologies, ZS Genetics, and Pacific Biosciences are some of the key players of this market.
KEY MARKET SEGMENTS
The global cancer genome sequencing market is segmented into two broad categories: technology and geography.
MARKET BY TECHNOLOGY
Second Generation Technology Platforms
– SOLiD sequencing (by ABI)
– Pyro-sequencing (by Roche)
– Bridge amplification sequencing technology (by Illumina)
Third Generation Technology Platforms
– Single Molecule Real Time (SMRT) sequencing (by Pacific Biosciences)
– Ion semiconductor sequencing.
– Nanopore sequencing (by Oxford)
– fluorescent resonant energy transfer (FRET) sequencing (by VisiGen biotechnologies)
MARKET BY GEOGRAPHY
– North America
For more information about this report visit https://www.researchandmarkets.com/research/x6gwtq/world_cancer